16
total announcements
CORONA.NS · 15 min delayed
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about its participation in an Analyst/Investor Conference on August 26, 2026, in Ahmedabad. The company officials will attend the conference to discuss publicly available information, and no unpublished price-sensitive information will be discussed.
CORONA Remedies Limited
CORONA Remedies Limited reported a 21.9% year-on-year revenue growth in Q1 FY27, surpassing its stated growth guidance of 15%. The company's India business delivered an impressive 22.7% year-on-year revenue growth, significantly outperforming the Indian Pharmaceutical Market, which grew by 11.6% during the same period.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about its participation in Analyst/Investor Conferences on August 13 and 14, 2026, in Mumbai. The company officials will attend the conferences and discuss publicly available information. No unpublished price sensitive information (UPSI) will be discussed.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'. The company has approved the unaudited standalone and consolidated financial results along with limited review reports for the first quarter and three months ended June 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about the link of recording for the Q1 FY27 earnings conference call, available on the company's website.
CORONA Remedies Limited
CORONA Remedies Limited has published unaudited financial results for the first quarter and three months ended on June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
CORONA Remedies Limited
CORONA Remedies Limited has released an investor presentation for Q1 FY27, highlighting its operational and financial performance, including revenue growth, improved rankings, and EU-GMP certification for its facilities.
CORONA Remedies Limited
CORONA Remedies Limited has announced its unaudited financial results for Q1FY27, reporting a revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y, driven by robust brand building and operational excellence.
CORONA Remedies Limited
CORONA Remedies Limited has submitted its financial results for Q1FY27, showing a revenue growth of 21.9% and a PAT growth of 30.1% Y-o-Y. The company has also announced the inauguration of its EU-GMP approved Female Hormone Manufacturing Facility and the integration of the Wokadine brand.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about the schedule of its Q1 FY27 earnings conference call to discuss the financial results for the first quarter and three months ended June 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has submitted the Exchange a copy Scrutinizer report of Annual General Meeting held on July 09, 2026, and informed the Exchange regarding voting results.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 09, 2026, where the company passed various resolutions including final dividend declaration, auditor appointment, and director re-appointment.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the first quarter ended June 30, 2026.
CORONA Remedies Limited
CORONA Remedies Limited has announced the commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad, marking a significant milestone in the company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.
CORONA Remedies Limited
CORONA Remedies Limited has announced the commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad. The facility has an annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels. This marks a significant milestone in the Company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.
CORONA Remedies Limited
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from July 01, 2026, until 48 hours from the declaration of the unaudited financial results for the first quarter and three months ending on June 30, 2026.